| 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 94,1 k € | -39.5% | 155,5 k € | +45.1% | 107,2 k € | -29.8% | 152,8 k € | +50.6% | 101,5 k € | +95.2% | 52,0 k € | +181.2% | -64,0 k € | -411.1% | 20,6 k € | -53.2% | 44,0 k € | -30.0% | 62,8 k € | +298.3% | -31,7 k € | |
| EBITDA | 91,0 k € | -21.3% | 115,7 k € | +10.6% | 104,5 k € | -11.7% | 118,3 k € | +29.8% | 91,1 k € | +76.0% | 51,8 k € | +156.1% | -92,4 k € | -20961.2% | 442,8 € | -99.0% | 43,6 k € | -30.2% | 62,4 k € | +294.7% | -32,0 k € | |
| Operating profit | 95,8 k € | +4.8% | 91,4 k € | -10.0% | 101,6 k € | -26.6% | 138,5 k € | +83.7% | 75,4 k € | +51.5% | 49,8 k € | +152.8% | -94,4 k € | -21412.9% | 442,8 € | -99.0% | 43,6 k € | -30.2% | 62,4 k € | +294.7% | -32,0 k € | |
| Profit/loss | 65,3 k € | +9.2% | 59,8 k € | -10.0% | 66,4 k € | -41.8% | 114,1 k € | +71.4% | 66,6 k € | +107.8% | 32,0 k € | +129.3% | -109,4 k € | -703.9% | -13,6 k € | -177.2% | 17,6 k € | -63.1% | 47,7 k € | +223.7% | -38,6 k € | |
| Equity | 571,8 k € | +12.9% | 506,5 k € | +13.4% | 446,7 k € | +17.5% | 380,3 k € | +25.8% | 302,4 k € | +28.2% | 235,8 k € | +15.7% | 203,7 k € | +222.6% | 63,2 k € | -17.7% | 76,8 k € | +29.8% | 59,1 k € | +417.9% | 11,4 k € | |
| Total assets | 1,3 M € | -4.9% | 1,4 M € | +40.3% | 1,0 M € | +43.0% | 704,6 k € | +63.0% | 432,3 k € | +9.9% | 393,3 k € | +20.8% | 325,5 k € | +50.4% | 216,4 k € | +19.7% | 180,8 k € | -11.4% | 204,0 k € | +68.0% | 121,4 k € | |
| Cash | — | 0,0 € | -100.0% | 118,2 k € | -36.1% | 185,1 k € | +170.2% | 68,5 k € | +0.1% | 68,4 k € | -57.3% | 160,2 k € | +229.7% | 48,6 k € | +117.8% | 22,3 k € | -24.8% | 29,7 k € | -60.9% | 75,8 k € | ||
| Debts | 772,6 k € | -14.8% | 906,7 k € | +61.6% | 560,9 k € | +72.9% | 324,3 k € | +149.8% | 129,8 k € | -17.6% | 157,5 k € | +38.4% | 113,8 k € | -25.7% | 153,2 k € | +47.3% | 104,1 k € | -28.2% | 144,8 k € | +31.7% | 110,0 k € | |
| Staff | — | 0 | 0 | — | — | — | — | — | — | — | — | |||||||||||
Private limited company · Gent · incorporated on 28/12/2012
Private limited company profitable and well capitalised. Cash position declining (-100.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
DGPharma is a Private limited company incorporated in 2012. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Gent.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette